100050
1400W dihydrochloride
≥95% (HPLC), nitric oxide synthase inhibitor, solid
别名:
1400W, N-(3-Aminomethyl)benzylacetamidine, 2HCl
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C10H15N3 · 2HCl
化学文摘社编号:
分子量:
250.17
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥95% (HPLC)
Form:
solid
Storage condition:
OK to freeze, desiccated (hygroscopic)
产品名称
1400W, A selective, cell-permeable, irreversible, slow, tight-binding inhibitor of inducible nitric oxide synthase (iNOS; Kd = 7 nM).
Quality Segment
assay
≥95% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, desiccated (hygroscopic)
color
white
solubility
water: 1 mg/mL, methanol: 5 mg/mL
shipped in
ambient
storage temp.
−20°C
InChI
1S/C10H16N3/c1-8(12)13-7-10-4-2-3-9(5-10)6-11/h2-5,13H,6-7,11-12H2,1H3/q+1/p+1
InChI key
FFSSUWWXUDLVQZ-UHFFFAOYSA-O
General description
A selective, cell-permeable, irreversible, slow, tight-binding inhibitor of inducible nitric oxide synthase (iNOS; Kd = 7 nM). Suitable for use in both in vitro and in vivo systems. Has a protective effect against cerebral ischemia by reducing ischemic lesion volumes. Exhibits greater than 5000- and 200-fold potency against human iNOS relative to eNOS and nNOS, respectively, and greater than 1000-fold potency against rat iNOS relative to eNOS.
A selective, irreversible, slow, tight binding inhibitor of inducible nitric oxide synthase (iNOS, Kd = 7 nM) both in vitro and in vivo. Has a protective effect against cerebral ischemia by reducing ischemic lesion volumes. Exhibits greater than 5000- and 200-fold potency against human iNOS relative to eNOS and nNOS, respectively, and greater than 1000-fold potency against rat iNOS relative to eNOS.
Biochem/physiol Actions
Cell permeable: yes
Kd = 7 nM against inducible nitric oxide synthase (iNOS)
Primary Target
iNOS
iNOS
Product does not compete with ATP.
Reversible: no
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable up to 3 months at -20°C.
Other Notes
Parmentier, S., et al. 1999. Br. J. Pharmacol.127, 546.
Cardenas, A., et al. 1998. Eur. J. Pharmacol. 354, 161.
Parrino, P.E., et al. 1998. Ann. Thorac. Surg. 66, 733.
Garvey, E.P., et al. 1997. J. Biol. Chem. 272, 4959.
Laszlo, F., and Whittle, B.J. 1997. Eur. J. Pharmacol. 334, 99.
Thomsen, L.L., et al. 1997. Cancer Res. 57, 3300.
Cardenas, A., et al. 1998. Eur. J. Pharmacol. 354, 161.
Parrino, P.E., et al. 1998. Ann. Thorac. Surg. 66, 733.
Garvey, E.P., et al. 1997. J. Biol. Chem. 272, 4959.
Laszlo, F., and Whittle, B.J. 1997. Eur. J. Pharmacol. 334, 99.
Thomsen, L.L., et al. 1997. Cancer Res. 57, 3300.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
Still not finding the right product?
Explore all of our products under 1400W
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable